| dbo:abstract |
Editas Medicine, ehemals Gengine, Inc., ist ein Biotechnologieunternehmen, das an Therapien auf der Grundlage der CRISPR/Cas-Methode forscht. Editas hat seinen Sitz in Cambridge, Massachusetts, und verfügt über Forschungseinrichtungen in Boulder, Colorado. (de) Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. (en) |
| dbo:assets |
5.08885E8 |
| dbo:equity |
2.62437E8 |
| dbo:foundedBy |
dbr:David_R._Liu dbr:J._Keith_Joung dbr:George_Church_(geneticist) dbr:Feng_Zhang dbr:Jennifer_Doudna |
| dbo:industry |
dbr:Pharmaceutical dbr:Biotechnology dbr:Genome_engineering |
| dbo:numberOfEmployees |
208 (xsd:nonNegativeInteger) |
| dbo:numberOfLocations |
2 (xsd:nonNegativeInteger) |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Editas_Medicine_logo.png?width=300 |
| dbo:wikiPageID |
49392319 (xsd:integer) |
| dbo:wikiPageLength |
15311 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1112516343 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Cambridge,_Massachusetts dbr:Sarepta_Therapeutics dbr:Bill_Gates dbr:Boulder,_Colorado dbr:David_R._Liu dbr:Beta_thalassemia dbr:Pharmaceutical dbr:University_of_California,_Berkeley dbr:In_vivo dbr:Intravitreal_injection dbr:J._Keith_Joung dbc:Biotechnology_companies_of_the_United_States dbc:Companies_listed_on_the_Nasdaq dbr:Russell_2000_Index dbr:T_cell_receptor dbr:George_Church_(geneticist) dbr:George_M._Church dbr:Sickle_cell_disease dbr:Chimeric_antigen_receptor dbc:Companies_based_in_Cambridge,_Massachusetts dbr:Bristol_Myers_Squibb dbr:Broad_Institute dbr:Celgene dbr:AbbVie dbr:Allergan dbr:FDA dbr:Feng_Zhang dbc:Gene_therapy dbr:Harvard_University dbr:Jennifer_Doudna dbc:Health_care_companies_based_in_Massachusetts dbc:Pharmaceutical_companies_of_the_United_States dbc:Pharmaceutical_companies_established_in_2013 dbr:Juno_Therapeutics dbr:Leber_congenital_amaurosis dbr:Biotechnology dbr:CRISPR_gene_editing dbr:Initial_public_offering dbr:Cas12a dbr:Cas9 dbr:Series_B dbr:Phases_of_clinical_research dbr:Polaris_Partners dbr:Third_Rock_Ventures dbr:Genome_engineering dbr:Flagship_Ventures dbr:Nucleases |
| dbp:assets |
5.08885E8 |
| dbp:assetsYear |
2019 (xsd:integer) |
| dbp:equity |
2.62437E8 |
| dbp:equityYear |
2019 (xsd:integer) |
| dbp:founded |
in Cambridge, Massachusetts (en) |
| dbp:founders |
dbr:David_R._Liu dbr:J._Keith_Joung dbr:George_Church_(geneticist) dbr:Feng_Zhang dbr:Jennifer_Doudna |
| dbp:hqLocationCity |
Cambridge, Massachusetts (en) |
| dbp:hqLocationCountry |
United States (en) |
| dbp:industry |
dbr:Pharmaceutical dbr:Biotechnology dbr:Genome_engineering (en) |
| dbp:keyPeople |
Gilmore O'Neill (en) |
| dbp:logo |
Editas Medicine logo.png (en) |
| dbp:name |
Editas Medicine (en) |
| dbp:numEmployees |
208 (xsd:integer) |
| dbp:numEmployeesYear |
2020 (xsd:integer) |
| dbp:numLocations |
2 (xsd:integer) |
| dbp:tradedAs |
dbr:Russell_2000_Index NASDAQ:EDIT (en) |
| dbp:type |
Public company (en) |
| dbp:wikiPageUsesTemplate |
dbt:Infobox_company dbt:Reflist dbt:Short_description dbt:Start_date_and_age dbt:URL |
| dcterms:subject |
dbc:Biotechnology_companies_of_the_United_States dbc:Companies_listed_on_the_Nasdaq dbc:Companies_based_in_Cambridge,_Massachusetts dbc:Gene_therapy dbc:Health_care_companies_based_in_Massachusetts dbc:Pharmaceutical_companies_of_the_United_States dbc:Pharmaceutical_companies_established_in_2013 |
| gold:hypernym |
dbr:Company |
| rdf:type |
owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 dbo:Organisation |
| rdfs:comment |
Editas Medicine, ehemals Gengine, Inc., ist ein Biotechnologieunternehmen, das an Therapien auf der Grundlage der CRISPR/Cas-Methode forscht. Editas hat seinen Sitz in Cambridge, Massachusetts, und verfügt über Forschungseinrichtungen in Boulder, Colorado. (de) Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. (en) |
| rdfs:label |
Editas Medicine (en) Editas Medicine (de) |
| owl:sameAs |
yago-res:Editas Medicine wikidata:Editas Medicine dbpedia-de:Editas Medicine https://global.dbpedia.org/id/2Bayd |
| prov:wasDerivedFrom |
wikipedia-en:Editas_Medicine?oldid=1112516343&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Editas_Medicine_logo.png |
| foaf:isPrimaryTopicOf |
wikipedia-en:Editas_Medicine |
| foaf:name |
Editas Medicine (en) |
| is dbo:wikiPageRedirects of |
dbr:Gengine,_Inc. |
| is dbo:wikiPageWikiLink of |
dbr:Cambridge,_Massachusetts dbr:Beam_Therapeutics dbr:David_R._Liu dbr:J._Keith_Joung dbr:Gene_therapy dbr:Louis_Tartaglia dbr:National_Organization_for_Rare_Disorders dbr:Locus_Biosciences dbr:CRISPR_Therapeutics dbr:Feng_Zhang dbr:Flagship_Pioneering dbr:Foresite_Capital dbr:Herpes_simplex_research dbr:Jennifer_Doudna dbr:Juno_Therapeutics dbr:Biotechnology_industry_in_Boston dbr:Gengine,_Inc. |
| is foaf:primaryTopic of |
wikipedia-en:Editas_Medicine |
